Cherif I, Tsevi Y M, Bawe L D, Guei C, Yao H
Université de Cocody, Centre hospitalier universitaire de Yopougon, Abidjan, Cote d'Ivoire.
Université de Lomé, Centre hospitalier universitaire Sylvanus Olympio, Lomé, Togo.
Med Trop Sante Int. 2021 Aug 20;1(3). doi: 10.48327/mtsibulletin.2021.118. eCollection 2021 Sep 30.
We report in this work the efficacy of highly active antiretrovirals (ARVs) alone in the treatment of diffuse infiltrative lymphocytosis syndrome (DILS) without the use of corticosteroids, which appears risky in patients living with HIV.
This is a 60-year-old HIV-positive patient, discovered during the etiological workup of renal failure, which revealed a non-nephrotic glomerular profile. The renal biopsy found an interstitial infiltrate of CD8 suggestive of DILS. Management consisted in starting ARV treatment alone (lamuvidine, abacavir and raltegravir) without associated corticosteroid therapy. The clinical evolution under treatment was marked by a recovery of the renal function with a creatininemia at 99 μmol/l, a regression of the proteinuria, a CD4 rate at 293/mm and an HIV viral load at 533.3 copies or 1.6 log in the space of 3 months.
DILS is a diffuse systemic disease in HIV patients who are usually under poor virological control. In view of the strong immunosuppression and the absence of other infiltrative diseases, it appeared to us to be risky and unjustified to add a corticosteroid therapy.
我们在本研究中报告了高活性抗逆转录病毒药物(ARV)单独用于治疗弥漫性浸润性淋巴细胞增多综合征(DILS)的疗效,而未使用皮质类固醇,因为在HIV感染者中使用皮质类固醇似乎存在风险。
这是一名60岁的HIV阳性患者,在肾衰竭的病因检查中被发现,检查显示为非肾病性肾小球病变。肾活检发现CD8间质浸润,提示为DILS。治疗方案为单独开始抗逆转录病毒治疗(拉米夫定、阿巴卡韦和拉替拉韦),不联合皮质类固醇治疗。治疗期间的临床进展表现为肾功能恢复,肌酐水平为99μmol/l,蛋白尿消退,CD4细胞计数为293/mm,HIV病毒载量在3个月内降至533.3拷贝或1.6 log。
DILS是一种通常病毒学控制不佳的HIV患者的弥漫性全身性疾病。鉴于其强烈的免疫抑制作用以及不存在其他浸润性疾病,我们认为添加皮质类固醇治疗似乎存在风险且不合理。